Standout Papers
Citation Impact
Citing Papers
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
2012 Standout
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
2010
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
2017
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
2013
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
2010
C-terminal region of activation-induced cytidine deaminase (AID) is required for efficient class switch recombination and gene conversion
2014 StandoutNobel
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
2010
Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair–Deficient Cancers
2011
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
Predictability of Genetic Interactions from Functional Gene Modules
2017
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
2011
BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
2013
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Human Papillomaviruses and the Interferon Response
2009
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
2009
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Triple negative breast cancer: unmet medical needs
2010
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2011
Hallmarks of Cancer: The Next Generation
2011 Standout
Target engagement imaging of PARP inhibitors in small-cell lung cancer
2018
Evidence that the Nijmegen breakage syndrome protein, an early sensor of double-strand DNA breaks (DSB), is involved in HIV-1 post-integration repair by recruiting the ataxia telangiectasia-mutated kinase in a process similar to, but distinct from, cellular DSB repair
2008
PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation
2011
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
2012
Genomic profiling of breast tumours in relation to BRCAabnormalities and phenotypes
2009
Triple-Negative Breast Cancer
2010 Standout
The DNA-damage response in human biology and disease
2009 StandoutNature
In vitro cytotoxicity, DNA cleavage and SOD-mimic activity of copper(II) mixed-ligand quinolinonato complexes
2012
Hypoxia, DNA repair and genetic instability
2008
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
2014
Interaction with DNA and different effect on the nucleus of cancer cells for copper(ii) complexes of N-benzyl di(pyridylmethyl)amine
2011
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
2015
Human papillomavirus oncoproteins: pathways to transformation
2010 Standout
BRCAness revisited
2016
Poly(ADP-ribosyl)ation in mammalian ageing
2007
PARP inhibitor combination therapy
2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
2016
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
Ovarian cancer
2014 Standout
Genital Papillomaviruses (PVs) and Epidermodysplasia Verruciformis PVs Occur in the Same Monkey Species: Implications for PV Evolution
1997
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
2013
The Human Papillomavirus 16 E6 Protein Binds to Tumor Necrosis Factor (TNF) R1 and Protects Cells from TNF-induced Apoptosis
2002
Olaparib: First Global Approval
2015
Potent oxidative DNA cleavage by the di-copper cytotoxin: [Cu2(μ-terephthalate)(1,10-phen)4]2+
2012
Classification of papillomaviruses
2004 StandoutNobel
Basic mechanisms of high‐risk human papillomavirus‐induced carcinogenesis: Roles of E6 and E7 proteins
2007
Using or abusing: viruses and the cellular DNA damage response
2007
Genetic Interactions in Cancer Progression and Treatment
2011
The resurgence of platinum-based cancer chemotherapy
2007 Standout
Synthesis, structural characterization and in vitro biological screening of some homoleptic copper(II) complexes with substituted guanidines
2011
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Advances in using PARP inhibitors to treat cancer
2012
Efficient DNA cleavage mediated by mononuclear mixed ligand copper(II) phenolate complexes: The role of co-ligand planarity on DNA binding and cleavage and anticancer activity
2012
DNA repair pathways as targets for cancer therapy
2008
The Human Papillomavirus 16 E6 Protein Binds to Fas-associated Death Domain and Protects Cells from Fas-triggered Apoptosis
2004
Copper in diseases and treatments, and copper‐based anticancer strategies
2009
Simultaneous Disruption of Two DNA Polymerases, Polη and Polζ, in Avian DT40 Cells Unmasks the Role of Polη in Cellular Response to Various DNA Lesions
2010
DNA repair deficiency as a therapeutic target in cancer
2008
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
2010
Oncogenic activities of human papillomaviruses
2009
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models
2015
PARP-2 Regulates SIRT1 Expression and Whole-Body Energy Expenditure
2011
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
2016
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
2012
Synthetic lethality as an engine for cancer drug target discovery
2019
DNA Damage, Aging, and Cancer
2009 Standout
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014
Breast cancer genomes — form and function
2010
Integrated genomic characterization of endometrial carcinoma
2013 StandoutNature
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
2010
The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300
1999
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status
2010
Predicting synthetic lethal interactions using conserved patterns in protein interaction networks
2019
A review of PARP inhibitors: from bench to bedside
2010
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
2013
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
2008
Human papillomavirus immortalization and transformation functions
2002
Phylogenetic Analysis of the Human Papillomavirus Type 2 (HPV-2), HPV-27, and HPV-57 Group, Which Is Associated with Common Warts
1997
The DNA damage response and cancer therapy
2012 Nature
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
2011 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling
2006
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
2010
Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival
2011
Papillomavirus E6 proteins
2008
Interaction of oncogenic papillomavirus E6 proteins with fibulin-1
2002
Synthetic lethality: the road to novel therapies for breast cancer
2016
The PtdIns(3,4)P2 phosphatase INPP4A is a suppressor of excitotoxic neuronal death
2010 StandoutNatureNobel
Genomic instability and the selection of treatments for cancer
2009
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
A Tri‐copper(II) Complex Displaying DNA‐Cleaving Properties and Antiproliferative Activity against Cancer Cells
2012
The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer
2011
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Comparison of papillomavirus and immunodeficiency virus evolutionary patterns in the context of a papillomavirus vaccine
2000
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
2013
The Hallmarks of Aging
2013 Standout
Copper Complexes as Anticancer Agents
2009
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 Standout
Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
2012
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
PARP inhibition: PARP1 and beyond
2010
Biomarkers for Early Detection and as Surrogate Endpoints in Cancer Prevention Trials: Issues and Opportunities
2010
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
2010
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
2016
The cancer genome
2009 StandoutNature
Deconstructing the molecular portraits of breast cancer
2010
Modulation of apoptosis by human papillomavirus (HPV) oncoproteins
2006
Genomic instability in breast cancer: Pathogenesis and clinical implications
2010
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
2009
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
2012
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
2016
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Analysis of genomic sequences of 95 papillomavirus types: uniting typing, phylogeny, and taxonomy
1995
Cytotoxic copper(II) complex of tripyridoquinoxaline with DNA hydrolase activity
2011
Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
2011
Practical Approach to Triple-Negative Breast Cancer
2017
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
2012
Hereditary gynaecological malignancies: advances in screening and treatment
2012
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
2011
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
2013
CBP/p300 in cell growth, transformation, and development
2000
Physiology meets biophysics: Visualizing the interaction of hypoxia-inducible factor 1α with p300 and CBP
2002 StandoutNobel
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
2012
Following the Path of the Virus: The Exploitation of Host DNA Repair Mechanisms by Retroviruses
2006
Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype
2010
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Human Papillomavirus Type 16 E7 Maintains Elevated Levels of the cdc25A Tyrosine Phosphatase during Deregulation of Cell Cycle Arrest
2002
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
2010
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
2013
Preventing Future Cancers by Testing Women With Ovarian Cancer forBRCAMutations
2009
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
2012 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospects
2008 StandoutNobel
Nuclease Activity via Self-Activation and Anticancer Activity of a Mononuclear Copper(II) Complex: Novel Role of the Tertiary Butyl Group in the Ligand Frame
2012
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Intratumor Heterogeneity: Evolution through Space and Time
2012
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer
2013
A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
2008
The DNA-damage response: new molecular insights and new approaches to cancer therapy
2009
Identification of simple arylfluorosulfates as potent agents against resistant bacteria
2021 StandoutNobel
Human Papillomavirus Oncoprotein E6 Inactivates the Transcriptional Coactivator Human ADA3
2002
Papillomavirus E6 and E7 proteins and their cellular targets
2007
ATM Mediates Cytotoxicity of a Mutant Telomerase RNA in Human Cancer Cells
2008 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Human Papillomavirus E6 Proteins Mediate Resistance to Interferon-Induced Growth Arrest through Inhibition of p53 Acetylation
2007
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
2009
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Advances in Copper Complexes as Anticancer Agents
2013 Standout
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
2006
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Direct Cellular Responses to Platinum-Induced DNA Damage
2007
c-Abl Regulates p53 Levels under Normal and Stress Conditions by Preventing Its Nuclear Export and Ubiquitination
2001 StandoutNobel
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
A Randomized Phase II Study of Veliparib with Temozolomide Or Carboplatin/Paclitaxel Versus Placebo with Carboplatin/Paclitaxel in Brca1 / 2 Metastatic Breast Cancer: Design and Rationale
2016
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Genomic diversity and evolution of papillomaviruses in rhesus monkeys
1997
Copper Curcuminoids Containing Anthracene Groups: Fluorescent Molecules with Cytotoxic Activity
2010
Works of Mark J. O’Connor being referenced
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
2012
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
2006
Functional Ex Vivo Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor Treatment
2014
Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
2010
Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft
2011
Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53 -Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
2009
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
2013
ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
2010
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
2015
Radical-induced DNA damage by cytotoxic square-planar copper(II) complexes incorporating o-phthalate and 1,10-phenanthroline or 2,2′-dipyridyl
2012
Sensitivity to Poly(ADP-ribose) Polymerase (PARP) Inhibition Identifies Ubiquitin-specific Peptidase 11 (USP11) as a Regulator of DNA Double-strand Break Repair
2010
Suppression of retroviral infection by the RAD52 DNA repair protein
2004
The overexpression of specialized DNA polymerases in cancer
2005
Bis-phenanthroline copper(ii) phthalate complexes are potent in vitro antitumour agents with ‘self-activating’ metallo-nuclease and DNA binding properties
2010
Targeting the DNA Damage Response in Cancer
2015
Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase
2005
Targeted cancer therapies based on the inhibition of DNA strand break repair
2007
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009 Standout
A Role for Polymerase η in the Cellular Tolerance to Cisplatin-Induced Damage
2005
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment
2012
Synthesis, catalase, superoxide dismutase and antitumour activities of copper(II) carboxylate complexes incorporating benzimidazole, 1,10-phenanthroline and bipyridine ligands: X-ray crystal structures of [Cu(BZA)2(bipy)(H2O)], [Cu(SalH)2(BZDH)2] and [Cu(CH3COO)2(5,6-DMBZDH)2] (SalH2=salicylic acid; BZAH=benzoic acid; BZDH=benzimidazole and 5,6-DMBZDH=5,6-dimethylbenzimidazole)
2007
Abstract 1775: Growth inhibitory effect of PARP inhibitor olaparib in gastric cancer cells
2010
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
2016
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition
2011
Abstract A114: Preclinical evaluation of the PARP inhibitor olaparib in homologous recombination deficient (HRD) MRE11 mutant microsatellite instable (MSI) colorectal cancer
2009
Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).
2014
Genomic characterization of long-term responders to olaparib.
2015
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
2008
Variation of human papillomavirus type 6 (HPV-6) and HPV-11 genomes sampled throughout the world
1995
Copper(II) Complexes of Salicylic Acid Combining Superoxide Dismutase Mimetic Properties with DNA Binding and Cleaving Capabilities Display Promising Chemotherapeutic Potential with Fast Acting in Vitro Cytotoxicity against Cisplatin Sensitive and Resistant Cancer Cell Lines
2012
Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to downregulate CBP/p300-mediated transactivation by p53
2000
Abstract 611: Exploratory analyses suggest ovarian tumors with somatic or germline loss of function mutations in BRCA1 or BRCA2 are biologically similar and sensitive to PARP inhibition
2015
Water-soluble bis(1,10-phenanthroline) octanedioate Cu2+ and Mn2+ complexes with unprecedented nano and picomolar in vitro cytotoxicity: promising leads for chemotherapeutic drug development
2011
The Human Papillomavirus Type 16 E6 Oncoprotein Can Down-Regulate p53 Activity by Targeting the Transcriptional Coactivator CBP/p300
1999
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
2008
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
2008